The approach varied, but typically, if a tumor showed MLH1/PMS2 deficiency and either BRAF positivity or hypermethylation, it was considered likely sporadic, and germline testing was discouraged or pursued only if clinical suspicion remained high. This evidence concerns the gene BRAF and neoplasm.